Re­gen­eron has a win­ner in Dupix­ent and big sales hopes. So why are so few pa­tients tak­ing it?

One of the true biotech suc­cess sto­ries, New York’s Re­gen­eron has set its am­bi­tions sky high with two block­busters in their back pock­et and some po­ten­tial win­ners in the pipeline. But one of those best­sellers, im­munol­o­gy med Dupix­ent, hasn’t tak­en off quite as ex­pect­ed.

De­spite more than three and a half years on the mar­ket and its par­ent com­pa­nies’ pitch as a bet­ter bi­o­log­ic for eczema, IL-4 med Dupix­ent is still sit­ting at a mea­ger 6% mar­ket share of its 2.2 mil­lion el­i­gi­ble pa­tients in the US, Re­gen­eron ex­ecs said on a fourth-quar­ter earn­ings call with an­a­lysts Fri­day.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.